Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.com 

Definium Therapeutics has turned from a high-risk bet into a much safer biotech investment after its single-dose DT120 cleared phase 3 in three of four major trials, all headed to the FDA together. Success in the fourth looks priced in, so full FDA approval is the next catalyst, plus possible Trump administration psychedelics moves. Analyst targets of $70-90 could be reached with commercialization in a couple of years, though more multibaggers are unlikely. Support should hold near $35. x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Compass Pathways has de-risked its regulatory and cash path, shifting the question from survival to how big COMP360 can become. The FDA granted rolling NDA review for COMP360, its synthetic psilocybin for treatment-resistant depression, with filing on track for Q4 2026 and 26-week COMP006 Part B data due early Q3. A priority review voucher could cut review to about 1-2 months, and $466 million of cash funds it into 2028. It stays high-risk, with approval, scheduling, coverage and adoption ahead. … Show more